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Introduction Introduction	cont’d ConclusionShingles	is	caused	by	the	reactivation	of	
VZV	due	to	a	decline	in	cell-mediated	
immunity	(Cohen	et	al.,	2013,	p.	217).		
Signs	and	symptoms	of	shingles	can	be	
vague	at	first,	including	malaise,	
headache,	itching,	tingling	and	localized	
pain	(Cohen	et	al.,	2013,	p.	218).	As	the	
virus	progresses	along	a	dermatome	and	
reaches	the	skin,	a	maculopapular	rash	
presents	unilaterally	within	7-10	days	
(Cohen	et	al.,	2013,	p.	218).	Treatment	
with	an	antiviral	medication,	such	as	
acyclovir,	within	72	hours	of	onset	of	
symptoms	is	currently	the	standard	of	care	
for	shingles	(Wilson,	2014,	p.	33).	
Complications	like	post-herpetic	neuralgia,	
cerebral	vasculitis	and	herpes	zoster	
ophthalmicus can	occur	after	a	shingles	
infection,	making	early	diagnosis	and	
treatment	crucial	(Cohen	et	al.,	2013,	p.	
219).	Zostavax is	the	only	vaccine	for	
shingles	that	is	approved	in	the	United	
States	and	is	recommended	by	the	CDC	for	
eligible	individuals	over	the	age	of	60	
(CDC,	2016).	
References
A	relatively	new	vaccine,	Zostavax,	is	
available	for	shingles.	Current	
recommendations	include	only	vaccinating	
individuals	over	the	age	of	60,	as	they	are	
the	highest	risk	(Neuzil &	Griffin,	2016).	It	
has	been	determined	through	several	
studies	that	the	vaccine	is	safe,	with	minor	
side	effects	including	redness	at	the	
injection	site	and	muscle	pain	(Simberkoff
et	al.,	2011,	p.	547).	The	effectiveness	of	
the	Zostavax vaccine	is	still	being	studied	
because	it	is	relatively	new,	but	thus	far,	
studies	have	shown	that	the	vaccine	is	
mildly	effective	for	an	average	of	five	
years	after	administration,	with	decreasing	
efficacy	after	the	first	year	of	
administration	(Schmader et	al.,	2012,	p.	
1323-1324).
In	the	United	States,	it	is	estimated	that	
95%	of	the	population	are	seropositive	for	
antibodies	to	the	varicella	zoster	virus	(VZV),	
putting	a	large	majority	of	the	population	at	
risk	for	developing	herpes	zoster,	otherwise	
known	as	shingles	(Hadley	et	al.,	2016).	Neuzil
and	Griffin	state	that	shingles	is	primarily	
dominant	in	the	older	population	and	affects	
over	half	a	million	people	over	the	age	of	60	
(2016).	 The	primary	VZV	is	expressed	as	
highly	contagious	chickenpox	in	children,	
which	is	a	viral	infection	that	manifests	as	a	
generalized	rash	with	maculopapular	lesions	
and	advances	to	vesicles	(Cohen,	Salbu,	
Frank,	&	Israel,	2013,	p.	217).	After	the	
primary	VZV	infection	dissipates,	the	VZV	lies	
dormant	in	the	affected	individual’s	dorsal	
ganglia	and	awaits	to	be	reactivated	(Cohen	
et	al.,	2013,	p	.217).	Reactivation	can	occur	
for	many	reasons,	but	the	most	frequent	are	
immunocompromised	patients,	such	
individuals	in	the	older	population	and	
patients	infected	with	HIV	(Cohen	et	al.,	2013,	
p.	218).	It	has	also	been	proposed	that	injury	
to	dermatomes	could	also	reactivate	VZV	as	
well	as	increased	psychological	stress	(Cohen	
et	al.,	2013,	p.	218).	Genetics,	specifically	the	
role	of	interleukin	10,	could	also	play	a	role	in	
the	reactivation	of	VZV	(Cohen	et	al.,	2013,	p.	
218).
Shingles	can	easily	be	misdiagnosed	if	a	
thorough	history	is	not	obtained	and	several	
key	features	in	the	clinical	exam	are	missed.	
In	the	early	stages	of	reactivation,	patients	
can	present	with	vague	symptoms,	such	as	
generalized	malaise,	headache,	itching,	
tingling	and	localized	pain	(Cohen	et	al.,	2013,	
p.	218-219).	As	the	virus	progresses,	a	
maculopapular	rash	presents	unilaterally	
along	a	dermatome	and	within	7-10	days	of	
the	initial	onset	of	symptoms,	the	
maculopapular	rash	eventually	ulcerates	and	
scabs	over	(Oakley	&	Goodband,	2013).	Acute	
pain	is	the	main	complaint	in	80%	of	patients	
50	years	and	older	and	the	pain	is	typically	
described	as	“stabbing”	or	“burning”	(Oakley	
&	Goodband,	2013).
Numerous	complications	ranging	in	severity,	
including	post-herpetic	neuralgia,	herpes	
zoster	ophthalmicus and	cerebral	arteritis,	
can	occur	with	shingles,	making	early	
recognition	and	treatment	crucial	(Cohen	et	
al.,	2013,	p.	219).	Treatment	with	acyclovir	
within	72	hours	of	onset	of	symptoms	is	the	
gold	standard	of	treatment	(Cohen	et	al.,	
2013,	p.	220).	A	combination	of	different	
NSAIDs	and	analgesics	are	used	to	treat	post-
herpetic	neuralgia,	which	is	the	most	
common	complication	of	shingles	(Cohen	et	
al.,	2013,	p.	221).
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Nursing	Implications
• One	day	to	three	weeks	prior	to	skin	
eruption,	patients	may	complain	of	
prodromal	symptoms	(Wilson,	2014,	p.	
32):
• Malaise	
• Fever
• Chills
• Myalgia	
• Headache
• Stomach	upset
• Acute	neuritis	(burning	
and	tingling)
• Pruritus
• As	the	virus	is	released	by	the	nerve	
endings	in	the	skin	and	it	replicates,	skin	
eruption	of	the	virus	occurs	(Wilson,	
2014,	p.	32):
• Unilateral	erythematous	
maculopapular	rash
• Over	the	next	7-10	days	after	skin	
eruption	the	rash	progresses	to	(Cohen,	
2013,	p.	219):
• Pustules	and	ulceration	
with	crusts	and	scabbing,	
which	can	last	for	30	days	
in	the	acute	phase
Signs	and	Symptoms
A	live	attenuated	VZV	vaccine,	Zostavax,	
was	approved	in	2006	to	prevent	the	
reactivation	of	VZV,	resulting	in	shingles.	It	
is	the	only	vaccine	for	shingles	allowed	in	
the	United	States.	Zostavax is	currently	
recommended	as	a	one-time	dose	(Cohen	
et	al.,	2013,	p.	222).	
Zostamax reduces	the	risk	of	developing	
shingles	by	51%	and	post-herpetic	neuralgia	
by	67%	(CDC,	2016).
The	CDC	recommends	that	people	over	the	
age	of	60	years	and	older	should	get	the	
Zostavax vaccine	(2016).
The	Zostavax shingles	vaccine	has	proven	to	
be	safe.	Minor	reactions	to	the	vaccine	
include	erythema,	swelling	and	tenderness	
at	the	injection	site	(Simberkoff et	al.,	2011,	
p.	547).
Several	studies	have	shown	that	Zostavax
decreases	in	efficacy	progressively,	with	it	
being	most	effective	during	the	first	year.	
After	the	first	year,	the	efficacy	decreases	
from	79.2%	to	54.9%	and	further	declines	to	
44.4%	in	years	2	and	3	(Schmader et	al.,	2012,	
p.	1323-1324).	
In	response	to	the	steady	decline	in	efficacy	
of	the	Zostavax injection	after	the	first	year,	a	
study	was	completed	to	determine	the	safety	
and	immunogenicity	of	giving	a	second	
booster	Zostavax injection	to	individuals	over	
the	age	of	70	and	who	have	already	had	a	first	
dose	of	the	vaccination.	The	results	revealed	
that	individuals	who	received	a	booster	
Zostavax injection	had	elicited	a	statistically	
significant	rise	in	VZV	antibody	titers,	
suggesting	a	second	injection	over	the	age	of	
70	may	be	needed	(Levin	et	al.,	2016,	p.	20-
21).
Shingles	Vaccination:	Is	it	worth	it?
Post-herpetic	neuralgia	
• Defined	as	pain	persisting	more	than	3	
months	after	the	onset	of	the	rash	in	the	
same	affected	area	(Hadley	et	al.,	2016).
• Affects	approximately	20%	of	shingles	
cases	in	ages	60-65	and	30%	in	ages	older	
than	80	(Wilson,	2014,	p.	34).
• Pathophysiology	includes	damage	to	
peripheral	nerves	that	lose	the	ability	to	
inhibit	nociception	pain	signals,	thus	
lowering	the	threshold	for	nociceptive	
pain	activation	and	produces	spontaneous	
ectopic	pain	discharges	(Neuzil &	Griffin,	
2016).	
• Pain	is	typically	described	as	either	a	
constant	deep,	aching	or	burning	pain	
(Neuzil &	Griffin,	2016).
• Patients	suffer	from	reduced	quality	of	
life,	physical	functioning	and	psychological	
well-being	(Wilson,	2014,	p.	34).
• Pain	management	can	be	difficult	and	
various	medications	may	need	to	be	tried	
before	pain	is	under	control.
• Current	guidelines	suggest	tricyclic	
antidepressants	(such	as	amitriptyline),	
alpha-2	delta	ligands	(such	as	gabapentin),	
tramadol	and	opioids	(usually	reserved	for	
adjunct	treatment)	(Neuzil &	Griffin,	
2016).
• Initiating	treatment	with	acyclovir	within	
72	hours	of	onset	symptoms	of	initial	
shingles	diagnosis	decreases	the	
development	of	post-herpetic	neuralgia	
(Neuzil &	Griffin,	2016).
Herpes	zoster	ophthalmicus
• Occurs	in	10-20%	of	herpes	zoster	cases	
(Vrcek,	Choudhury,	&	Durairaj,	2017,	p.	
21).
• Occurs	when	reactivation	of	VZV	presents	
in	the	first	division	of	the	trigeminal	nerve	
(Vrcek et	al.,	2017,	p.	21).
• Optic	neuritis,	retinal	necrosis,	nummular	
keratitis	and	uveitis	can	develop	and	could	
potentially	result	in	permanent	loss	of	
vision	(Vrcek et	al.,	2017,	p.	22).
• A	rash	typically	involves	the	periocular	
skin	and	the	tip	of	the	nose	(called	the	
Hutchinson	sign)	(Vrcek et	al.,	2017,	p.	22)
• If	the	health	care	provider	suspects	any	
ophthalmic	involvement,	a	consultation	
with	an	ophthalmologist	is	recommended	
(Vrcek et	al.,	2017,	p.	24).
• Treatment	needs	to	be	quick	and	
aggressive	to	avoid	permanent	damage	to	
the	eye	(Wilson,	2014,	p.	33).	
Underlying	
Pathophysiology
Herpes	zoster	is	the	secondary	
infection	of	VZV,	with	the	primary	
infection	being	the	chickenpox	which	is	
more	prevalent	in	children	(Cohen	et	al.,	
2013,	p.	217).	Following	the	resolution	of	
chickenpox,	the	virus	remains	dormant	in	
the	dorsal	root	ganglia	and	is	protected	
from	the	host’s	immune	system	by	the	
antibodies	that	were	made	during	the	
primary	VZV	infection	(Cohen	et	al.,	2013,	
p.	217).	Cell	mediated	immunity	(CMI)	is	
quite	successful	at	keeping	VZV	in	the	
dormancy	phase	but	as	CMI	declines	with	
age,	immunosuppression	or	increased	
psychological	or	physical	stress,	VZV	can	
reactivate,	resulting	in	herpes	zoster	
(Wilson,	2014,	p.	31-32).	Once	VZV	is	
reactivated,	the	T	cells	of	the	host’s	cell-
mediated	immune	system	carry	the	virus	
through	the	dorsal	root	ganglia	and	the	
dormant	virus	begins	to	replicate	and	
proliferate	(Cohen	et	al.,	2013,	p.	218).	
VZV	then	descends	through	the	neural	
pathways	to	the	peripheral	sensory	roots,	
following	a	distinct	dermatome	(Cohen	et	
al.,	2013,	p.	218)	This	results	in	pain	and	
numbness;	however,	a	rash	may	not	yet	
be	visible.		When	the	virus	reaches	the	
dermis	and	epidermis	of	the	affected	
dermatome,	skin	inflammation	becomes	
evident	and	the	emergence	of	
maculopapular	lesions	occurs	(Cohen	et	
al.,	2013,	p.	218).	These	lesions	
progressively	develop	into	lesions	filled	
with	VZV	infected	fluid	(Cohen	et	al.,	
2013,	p.	218).	Typically,	within	10	days,	
the	lesions	rupture	and	form	scabs,	which	
signals	the	ending	stages	of	the	infection	
(Cohen	et	al.,	2013,	p.	218).	
Significance	of	
Pathophysiology
According	to	the	Centers	for	Disease	
Control	and	Prevention	(CDC),	in	the	United	
States,	1	million	people	are	diagnosed	with	
shingles	each	year	and	1	out	of	every	3	
people	will	get	shingles	in	their	life	time	
(2016).	Herpes	zoster	can	be	more	
exaggerated	and	deleterious	in	
immunocompromised	individuals,	such	as	
advanced	age,	individuals	infected	with	HIV,	
individuals	who	have	had	an	organ	
transplant,	individuals	on	
immunosuppressive	drugs	and	those	with	
neoplastic	diseases	(Cohen	et	al.,	2013,	p.	
218).	Immunocompromised	individuals	are	
more	likely	for	VZV	to	reactivate	and	are	
more	likely	to	have	more	serious	
complications	from	shingles,	such	as	skin	
necrosis	and	scarring	(Cohen	et	al.,	2013,	p.	
218).	Presentation	of	a	rash	along	more	than	
one	dermatome	or	in	a	bilateral	pattern	can	
occur	in	immunocompromised	patients	
(Wilson,	2014,	p.	32).	Also,	severe	
complications	of	shingles	can	decrease	
quality	of	life,	such	as	post-herpetic	
neuralgia,	cerebral	arteritis	that	could	
potentially	lead	to	a	stroke,	and	herpes	
zoster	ophthalmicus (Cohen	et	al.,	2013,	p.	
219).	Seeing	that	shingles	is	a	prevalent	
disorder	in	the	United	States	and	that	
shingles	can	potentially	have	harmful	effects	
on	both	immunocompromised	and	
immunocompetent	populations,	it	is	
important	for	health	care	providers	to	
accurately	and	quickly	diagnose	shingles.	
Understanding	the	underlying	
pathophysiology	of	shingles	and	the	process	
in	which	the	disorder	presents	itself	will	aid	in	
swift	and	appropriate	diagnosis,	thus	
hopefully	preventing	adverse	complications	
by	treating	the	patient	correctly.	For	
example,	the	health	care	provider	gathering	a	
detailed	history	including	if	the	patient	has	
had	chickenpox,	recent	or	chronic	illness	or	
stressors,	and	medication	the	patient	is	
taking	along	with	subjective	information	from	
the	patient	stating	they	are	having	numbness	
or	pain	along	a	specific	dermatome,	could	
lead	to	an	early	diagnosis	of	shingles	and	
appropriate	treatment	could	be	started	
earlier,	thus	limiting	the	course	of	the	virus	
and	any	potential	complications	(Corden,	
2014,	p.	60).	
Treatment
• Treatment	with	antiviral	therapy	within	72	
hours	of	lesion	onset	is	key	treatment	to	
success	(Wilson,	2014,	p.	33).	This	is	
important	because	starting	therapy	quickly	
limits	the	damage	to	the	sensory	nerves	
from	replicating	the	virus,	thus	preventing	
further	complications	and	spread	of	the	
lesions	(Wilson,	2014,	p.	33).
• Antivirals	can	include	(Wilson,	2014,	p.	33):
• Acyclovir	administered	
orally	5	times	a	day	for	7-10	
days
• Famciclovir administered	
orally	every	8	hours	for	7	
days
• Valacyclovir administered	
three	times	a	day	for	7	days
• Prescribing	corticosteroids	for	shingles	is	
controversial	among	health	care	providers,	
but	several	randomized	control	trials	have	
shown	that	corticosteroids	in	addition	to	
acyclovir	can	lessen	the	amount	of	pain	of	
acute	shingles	(Wilson,	2014,	p.	33).
• Consider	prescribing	
corticosteroids	with	
antivirals	in	patients	over	50	
who	have	moderate-to-
severe	pain	and	who	have	
no	contraindications	
(Wilson,	2014,	p.	33).
• A	tapered	dose	of	
prednisone	starting	at	60	
mg	daily	for	10-14	days	is	
typically	prescribed	(Wilson,	
2014,	p.	33).	
• The	mild-to-moderate	acute	pain	from	
shingles	can	be	treated	with	NSAIDs,	
acetaminophen	and	tramadol,	whereas	
moderate-to-severe	pain	can	be	treated	
with	opioids	such	as	oxycodone	(Wilson,	
2014,	p.	33).	
• Since	shingles	can	be	quite	painful	and	
can	progress	to	serious	complications	if	
not	treated	quickly,	it	is	important	for	
health	care	providers,	such	as	family	
nurse	practitioners	(FNPs),	to	accurately	
recognize,	diagnose	and	treat	shingles.	
• Evaluation	of	herpes	zoster	begins	with	a	
complete	history,	including	a	history	of	
primary	VZV	infection	(chickenpox).	FNPs	
should	also	target	their	questioning	to	
determine	if	the	patient	is	potentially	
immunocompromised,	as	shingles	can	be	
more	aggressive	and	has	the	potential	
for	more	deleterious	complications	in	
those	that	are	immunosuppressed.	A	
thorough	physical	examination	and	a	
detailed	review	of	systems	should	be	
completed	to	exclude	other	differential	
diagnoses	(Vreck et	al.,	2017,	p.	24).
• Diagnosis	can	be	made	by	the	
characteristic	appearance	of	unilateral	
maculopapular	lesions	along	one	
dermatome.	Early	diagnostic	criteria	
includes	systemic	manifestations	like	
fever	and	malaise	as	well	as	localized	
manifestations	along	the	affected	
dermatome,	such	as	pain,	burning	
sensation,	itching,	hyperesthesia	and	
paresthesia	(Corden,	2014,	p.	60).	
• It	is	also	important	for	FNPs	to	educate	
their	patients	about	shingles.	Educating	
patients	that	shingles	is	not	contagious,	
however,	the	virus	that	causes	shingles,	
VZV,	can	be	spread	to	a	person	who	has	
never	had	chickenpox	is	imperative.	The	
exposed	person	could	potentially	
develop	chickenpox,	not	shingles.		VZV	is	
typically	spread	through	direct	contact	
with	fluid	from	the	shingle	rash’s	
vesicles.	Covering	the	rash	during	the	
vesicle	phase	of	the	infection	can	
decrease	the	risk	of	transmitting	VZV	
(Wilson,	2014,	p.	32).	
• Affected	individuals	need	to	be	advised	
to	avoid	contact	with	pregnant	women,	
those	who	have	not	had	chickenpox	and	
anyone	who	is	immunocompromised	
(Corden,	2014,	p.	62).
• Assessing	the	patient’s	level	pain	is	
necessary,	as	shingles	can	be	painful.
• Supportive	treatments	such	as	calamine	
lotion	and	cold	compresses	over	weeping	
blisters	for	20	minutes	three	times	a	day	
could	be	suggested	to	aid	with	the	pain	
and	itching	associated	with	shingles.	
Also,	the	FNP	could	suggest	that	the	
patient	wear	loose-fitting	clothing	to	
avoid	friction	against	the	rash.	(Corden,	
2014,	p.	62).	
• Recommending	the	Zostavax vaccine	to	
eligible	patients	over	the	age	of	60	
should	be	considered	by	FNPs	(CDC,	
2016).
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